Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
PEGS Boston SummitPEGS Boston Summit
Not Confirmed
Not Confirmed
11 May-15 November, 2026
STLE Annual MeetingSTLE Annual Meeting
Not Confirmed
Not Confirmed
17-21 May, 2026
Biogas AmericasBiogas Americas
Not Confirmed
Not Confirmed
18-21 May, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
PEGS Boston Summit
Not Confirmed
Contact SupplierPEGS Boston Summit
PEGS Boston SummitPEGS Boston Summit
Industry Trade Show
Not Confirmed
11 May-15 November, 2026
STLE Annual MeetingSTLE Annual Meeting
Industry Trade Show
Not Confirmed
17-21 May, 2026
Biogas AmericasBiogas Americas
Industry Trade Show
Not Confirmed
18-21 May, 2026
Digital content
NEWS #PharmaBuzz
15 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/15/3219231/0/en/Stablepharma-and-AFT-Pharmaceuticals-NZX-AFT-ASX-AFP-partner-to-address-multi-billion-dollar-anti-infective-and-oncology-therapeutics-market.html
12 Nov 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/aft-pharmaceuticals-brings-next-generation-liposomal-collagen-and-wellness-range-to-the-us-market-302612533.html
20 Jul 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/07/20/2708394/0/en/Crossject-signs-new-licensing-agreement-on-ZENEO-Midazolam-epilepsy-rescue-therapy-with-AFT-Pharmaceuticals-for-Australia-New-Zealand.html
28 Apr 2021
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/hikma-announces-exclusive-agreement-with-aft-pharmaceuticals-for-injectable-non-opioid-pain-medication-combogesic-iv-in-the-us-301279371.html
28 Apr 2021
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/hikma-announces-exclusive-agreement-with-aft-pharmaceuticals-for-injectable-non-opioid-pain-medication-combogesic-iv-in-the-us-301279371.html
26 Nov 2019
// GLOBE NEWSWIRE
https://www.globenewswire.com/news-release/2019/11/25/1952283/0/en/BioSyent-Signs-Exclusive-Agreement-for-Pain-Management-Products.html
Drugs in Development
Details:
Rapamycin is a antibiotic drug, which is currently being evaluated in Phase II clinical studies for the treatment of port-wine stain.
Lead Product(s): Sirolimus
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 27, 2026
Lead Product(s) : Sirolimus
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Rapamycin Dose-Ranging Efficacy Study in Port Wine Stains
Details : Rapamycin is a antibiotic drug, which is currently being evaluated in Phase II clinical studies for the treatment of port-wine stain.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 27, 2026
Details:
As part of the agreement, an undisclosed vaccine targeting infection will be developed to address key focus areas.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Vaccine
Recipient: Stablepharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 15, 2026
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery Platform
Recipient : Stablepharma
Deal Size : Undisclosed
Deal Type : Agreement
Stablepharma, AFT Partner for Anti-Infective and Oncology Therapeutics Market
Details : As part of the agreement, an undisclosed vaccine targeting infection will be developed to address key focus areas.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
January 15, 2026
Details:
Acetaminophen is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Acute Pain.
Lead Product(s): Paracetamol,Ibuprofen
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 06, 2025
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Combogesic® IV (Intravenous) in Pediatric Patients With Acute Pain
Details : Acetaminophen is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Acute Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 06, 2025
Details:
Acetaminophen is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Pain, Postoperative.
Lead Product(s): Paracetamol,Ibuprofen
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 05, 2025
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Combogesic® 325 in Adolescent Patients With Moderate to Severe Postoperative Pain Asso...
Details : Acetaminophen is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Pain, Postoperative.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 05, 2025
Details:
Under the agreement, AFT will commercialise ZENEO® Midazolam, a combination of the single use needle-free auto injector ZENEO® and the drug product midazolam, in epileptic seizures in Australia and New Zealand.
Lead Product(s): Midazolam
Therapeutic Area: Neurology Brand Name: Zepizure
Study Phase: Approved FDFProduct Type: Controlled Substance
Recipient: Crossject
Deal Size: $0.7 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 20, 2023
Lead Product(s) : Midazolam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Crossject
Deal Size : $0.7 million
Deal Type : Licensing Agreement
Crossject Signs New Licensing Agreement on ZENEO® Midazolam Epilepsy Rescue Therapy with AFT Phar...
Details : Under the agreement, AFT will commercialise ZENEO® Midazolam, a combination of the single use needle-free auto injector ZENEO® and the drug product midazolam, in epileptic seizures in Australia and New Zealand.
Product Name : Zepizure
Product Type : Controlled Substance
Upfront Cash : Undisclosed
July 20, 2023
Details:
Maxigesic (paracetamol) IV is a novel, dual mode-of-action, non-opioid pain treatment delivered through intravenous (IV) infusion for use post-operatively in hospitals or when patients cannot take medicine orally.
Lead Product(s): Paracetamol,Ibuprofen
Therapeutic Area: Neurology Brand Name: Maxigesic
Study Phase: Approved FDFProduct Type: Miscellaneous
Recipient: Salus Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 24, 2023
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Salus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Hyloris Announces Commercial Partnership for Maxigesic IV in 9 European Countries
Details : Maxigesic (paracetamol) IV is a novel, dual mode-of-action, non-opioid pain treatment delivered through intravenous (IV) infusion for use post-operatively in hospitals or when patients cannot take medicine orally.
Product Name : Maxigesic
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 24, 2023
Details:
Under the terms of the agreement, AFT has exclusive rights to commercialize QRX003, a potential treatment for Netherton Syndrome in Australia and New Zealand, upon the receipt of regulatory approvals in both territories.
Lead Product(s): QRX003
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Quoin Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 08, 2021
Lead Product(s) : QRX003
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Quoin Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, AFT has exclusive rights to commercialize QRX003, a potential treatment for Netherton Syndrome in Australia and New Zealand, upon the receipt of regulatory approvals in both territories.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 08, 2021
Details:
Hikma gets rights for the sales, marketing and distribution of Combogesic® IV in the US. Combogesic® IV is a patented intravenous formulation developed as a line extension to Maxigesic tablets, used post-operatively in hospitals when patients cannot take a medicine orally.
Lead Product(s): Paracetamol,Ibuprofen
Therapeutic Area: Neurology Brand Name: Combogesic IV
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Hikma Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 28, 2021
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Hikma Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Hikma gets rights for the sales, marketing and distribution of Combogesic® IV in the US. Combogesic® IV is a patented intravenous formulation developed as a line extension to Maxigesic tablets, used post-operatively in hospitals when patients cannot ta...
Product Name : Combogesic IV
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 28, 2021
Details:
Extension of agreement with AFT Pharmaceuticals grants Desitin Arzneimittel GmbH exclusive license and supply rights for TMB-002 in Europe.
Lead Product(s): Sirolimus
Therapeutic Area: Dermatology Brand Name: Pascomer
Study Phase: Phase IIProduct Type: Antibiotic
Sponsor: Timber Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 17, 2021
Lead Product(s) : Sirolimus
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Timber Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Timber Pharmaceuticals’ Development Partner, AFT Pharmaceuticals, Enters into Licensing Agreemen...
Details : Extension of agreement with AFT Pharmaceuticals grants Desitin Arzneimittel GmbH exclusive license and supply rights for TMB-002 in Europe.
Product Name : Pascomer
Product Type : Antibiotic
Upfront Cash : Undisclosed
March 17, 2021
Details:
Acetaminophen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pain, Postoperative.
Lead Product(s): Paracetamol,Ibuprofen
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 02, 2019
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Maxigesic® IV Phase 3 Exposure Study
Details : Acetaminophen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pain, Postoperative.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 02, 2019
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
Inspections and registrations
ABOUT THIS PAGE
Share 
